CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.
about
Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progressionA human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFbLARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associatedDeregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancerCrystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9An HIV feedback resistor: auto-regulatory circuit deactivator and noise bufferCyclin Box Structure of the P-TEFb Subunit Cyclin T1 Derived from a Fusion Complex with EIAV TatStructural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAVSubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesIdentification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 TatMutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cellsChemical Composition and In Vitro Cytotoxicity of Essential Oils from Leaves and Flowers of Callistemon citrinus from Western HimalayasUp-regulation of P-TEFb by the MEK1-extracellular signal-regulated kinase signaling pathway contributes to stimulated transcription elongation of immediate early genes in neuroendocrine cellsCyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosisFunctional characterization of a new member of the Cdk9 family in Aspergillus nidulans.Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation.P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.A transcriptional activator is part of an SCF ubiquitin ligase to control degradation of its cofactorsThe Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiationThe Caenorhabditis elegans replication licensing factor CDT-1 is targeted for degradation by the CUL-4/DDB-1 complexOncogenic aberrations of cullin-dependent ubiquitin ligases.Use of ATP analogs to inhibit HIV-1 transcription.Orphan kinases turn eccentric: a new class of cyclin Y-activated, membrane-targeted CDKsDirect inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts.Selective control of gene expression by CDK9 in human cellsThe emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.CDK9/cyclin complexes modulate endoderm induction by direct interaction with Mix.3/mixer.Transcription factor IIS cooperates with the E3 ligase UBR5 to ubiquitinate the CDK9 subunit of the positive transcription elongation factor B.Coordinated activation of the origin licensing factor CDC6 and CDK2 in resting human fibroblasts expressing SV40 small T antigen and cyclin E.Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.UV Induces p21 rapid turnover independently of ubiquitin and Skp2.Human immunodeficiency virus type 1 infection induces cyclin T1 expression in macrophages.Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone.SAR study on N2,N4-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents.MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9.MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discoveryThe CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP
P2860
Q24301464-E8122D72-5B62-4097-9BBE-6FCF2CA6961BQ24561968-F58FA931-5E52-4F46-B392-07D35609D881Q24646322-DBA57321-329C-422E-AF3D-34C15FEF3990Q24648025-7804C7FF-ABFF-466F-B903-184317080A68Q24683471-DBD57B08-741C-4A99-BB31-C51C17D5F179Q27334904-11BBFE8E-203B-490F-B8C4-45980D41C273Q27645094-D1DBFACD-7829-47D7-9908-64A96F11460BQ27652984-6C918939-4985-4785-A3C6-C464F6F1F63FQ27675842-E7A58B2E-4823-4138-B3B4-F88277EEA677Q28247078-5660036F-FC4A-457B-AF53-EAE01CD0E3A9Q28259285-B8B448AD-4B57-4892-8DE3-1BCF82A6C8C4Q28547515-E2B74B68-CE04-4F4B-A222-B75A13914261Q28572356-B9E1EB3C-17E9-4F61-B582-DAD3ADDD067FQ28732702-C16998FE-0D2D-4390-87B8-34DA4F2735F7Q30497730-A4711B2A-54F7-427C-B431-D5E3C9883DEFQ33930482-95A8F023-7C00-48AD-86CB-6CD823D7DAB6Q34144747-994042B4-6BA1-4BDD-A077-37161C2ED1D3Q34365839-402F6292-A405-40C6-8351-62A7EE68118BQ34517610-A48F226B-0956-4F06-9FA4-9BB94F582775Q35072999-39F6B33D-C0FC-46A8-8A4E-80AD1F4088F6Q35641855-CDA8878B-6B32-4E42-83E0-E2CE425A1888Q35691547-30673AA6-07CE-40B0-8335-6DA70EF025D9Q36202709-26C7F62C-B927-4FA0-A803-BE89F576461DQ36392120-B41C9DE9-E655-4411-B2D0-EA27E8727F0DQ36419687-DBC4A24E-FC2D-47D6-8104-7253A993A4A1Q36727304-6CE667D2-271E-4AC2-ABCE-BD946AD6B654Q37437860-E970F4D4-5FCB-4106-AF7A-D64634D21C6DQ39005055-98DB4635-5051-4AF5-88E8-D797C58A373FQ39429987-CD38F4C0-AC72-4B44-A919-0775CF2D5F94Q39624534-CA93B582-2E7C-4D1E-8901-E6BBCC79FDC1Q39868304-BAFD53F5-DABE-4F3B-91CB-1C002A495E3AQ40079572-3F490138-FAD5-457C-8852-E01DAF137B58Q40262460-C101A48D-7A7B-4A79-AF7B-D8213EEE8581Q41039158-98C40A52-4AFA-45DB-BB33-8EB897698507Q45335193-921D7080-60AA-4106-A77B-8534AF71E838Q52717605-5BCDF6EE-9CD7-45B4-9313-7919F7CDD273Q53166772-E0193A3A-6CBC-46A1-A8F6-E5D6ABF65692Q54112430-C389726B-4089-4772-9747-4721FB160815Q58547215-CBC3165E-EF9E-4031-B183-A2C2F3465DDFQ58744597-8F1F1ADE-9803-4817-93B2-6E4A70F4E9D2
P2860
CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
CDK9 is constitutively express ...... ession is independent of SKP2.
@ast
CDK9 is constitutively express ...... ession is independent of SKP2.
@en
type
label
CDK9 is constitutively express ...... ession is independent of SKP2.
@ast
CDK9 is constitutively express ...... ession is independent of SKP2.
@en
prefLabel
CDK9 is constitutively express ...... ession is independent of SKP2.
@ast
CDK9 is constitutively express ...... ession is independent of SKP2.
@en
P2093
P2860
P1476
CDK9 is constitutively express ...... ession is independent of SKP2.
@en
P2093
Dale S Haines
Joaquim Calbó
Judit Garriga
May Truongcao
Renée M Marshall
Sabyasachi Bhattacharya
Xavier Graña
P2860
P304
P356
10.1128/MCB.23.15.5165-5173.2003
P407
P577
2003-08-01T00:00:00Z